Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma

Pharmacotherapy

Volumn 26, Issue 8 I, 2006, Pages 1205-1206

  Kenealy, Melita K ^a   Prince, H Miles ^a   Hönemann, Dirk ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Bortezomib; Multiple myeloma; TLS; Tumor lysis syndrome

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; LACTATE DEHYDROGENASE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; BONE MARROW SUPPRESSION; CLINICAL TRIAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; SHORT SURVEY; TUMOR LYSIS SYNDROME;

ADULT; AGED; BORONIC ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; TUMOR LYSIS SYNDROME;

EID: 33746700799     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.8.1205     Document Type: Short Survey

References (7)

1. Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005;25:1820-5.
2. Athanasios B, Fassas K, Desikan K, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haem 1999;105:938-41.
3. Cany L, Fitoussi O, Boiron JM, Marit G. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma [letter]. J Clin Oncol 2002;20;2212.
4. Fuente N, Mane J, Barcelo R, et al. Tumor lysis syndrome in a multiple myeloma treated with thalidomide [letter]. Ann Oncol 2004;15:537.
5. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004;130:623-5.
6. Mehta J, Jakob C, Singhal S, et al. Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma [abstr]. Blood 2003;102:5273.
7. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.